Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Elicio Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$9.95
52 Haftanın En Yüksek Seviyesi	US$14.93
52 Haftanın En Düşük Seviyesi	US$5.24
Beta	1.45
1 Aylık Değişim	-16.94%
3 Aylık Değişim	13.71%
1 Yıllık Değişim	75.80%
3 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-45.16%

Son Haberler & Güncellemeler

Anlatı Güncellemesi • May 21

Favorable Auction Dynamics

While Merck and Amgen are the frontrunners for a KRAS-driven partnership, Elicio’s AMP platform is particularly attractive to a broader subset of "Big Pharma" companies that are currently facing a specific strategic gap: the inability of their existing portfolios to penetrate "cold" tumors like pancreatic (PDAC) and colorectal (CRC) cancers. It is most probable that big pharma is conducting due diligence into RVMD and ELTX in parallel and evaluating outcomes and potential synergies with their existing portfolios.

Anlatı Güncellemesi • May 05

Valuation: 15x upside potential

Determining the valuation for Elicio Therapeutics (ELTX) requires balancing the high-cost nature of specialized immunotherapy with the massive patient populations affected by KRAS mutations. Based on current oncology benchmarks and the clinical profile of the AMP-7P vaccine, here is the projected economic outlook.

Anlatı Güncellemesi • Apr 29

Study on track for success

As of April 28, 2026, based on the enrollment completion of the AMPLIFY-7P Phase 2 study in November 2024, approximately 40% to 45% of the MRD-negative cohort should have progressed by now if there were no treatment effect. This calculation is based on the clinical parameters and natural history data provided in the sources: 1.

Recent updates

Anlatı Güncellemesi • May 21

Favorable Auction Dynamics

Anlatı Güncellemesi • May 05

Valuation: 15x upside potential

Anlatı Güncellemesi • Apr 29

Study on track for success

Anlatı Güncellemesi • Feb 21

10 mg adjuvant = 100% mKRAS specific T-cell response rate

The 10 mg dose of Amph-CpG-7909 improves vaccine efficacy by providing an optimized level of Toll-like receptor 9 (TLR-9) stimulation that is precisely targeted to the lymph nodes, resulting in a 100% T cell response rate and significantly enhanced anti-tumor activity compared to lower doses. The specific mechanisms by which this dose and formulation improve efficacy include: 1.

Analiz Makalesi • Feb 10

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Anlatı Güncellemesi • Jan 18

80-90% prob of success

Assuming a conservative 16-month median Disease-Free Survival (DFS) for the observation group—consistent with a nationwide, unselected (MRD-agnostic) surgical PDAC population—the probability that the AMPLIFY-7P Phase 2 study will show a statistically significant improvement in the treatment arm is estimated to be 80–90%. While the 16-month baseline represents a significantly more durable control group than the 5.0–6.4 month median seen in MRD-positive patients, the following factors derived from the sources support this high estimate: 1.

Seeking Alpha • Nov 07

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Summary ELTX is continuing its work on a KRAS vaccine in PDAC, with a phase 2 trial set to read out any day now. Earlier signals of efficacy of their phase 2 trial have shown biological correlation that suggests activity, but we still need to see outcomes of treatment. The company is heavily reliant on a positive read out in order to raise funds for further development. The potential upside here outweighs the admittedly huge downside risk, though. Read the full article on Seeking Alpha

Analiz Makalesi • Aug 30

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Hissedar Getirileri

	ELTX	US Biotechs	US Pazar
7D	-6.4%	1.2%	1.0%
1Y	75.8%	34.9%	28.7%

Getiri vs. Endüstri: ELTX geçen yıl % 34.9 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: ELTX geçen yıl % 28.7 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is ELTX's price volatile compared to industry and market?
ELTX volatility
ELTX Average Weekly Movement	13.1%
Biotechs Industry Average Movement	11.0%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.4%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ELTX hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: ELTX 'nin haftalık oynaklığı ( 13% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	33	Bob Connelly	elicio.com

Klinik aşamada bir biyoteknoloji şirketi olan Elicio Therapeutics, Inc. kanser tedavisi için immünoterapiler geliştirmektedir. Lider ürün adayı ELI-002, yedi Kirsten sıçan sarkomu viral onkogen homolog sürücü mutasyonu için Faz II klinik çalışmalarında olan multivalent lenf nodu hedefli bir amfifil (AMP) peptid aşısıdır. Şirket ayrıca mutant b-raf murin sarkom viral onkogen homolog B1-(BRAF) sürücülü kanserler için multivalent lenf nodu hedefli AMP peptit tedavisi olan ELI-007'yi ve mutasyona uğramış tümör proteini p53 eksprese eden kanserlerin tedavisi için preklinik çalışmalarda multivalent lenf nodu hedefli AMP peptit aşısı olan ELI-008'i geliştirmektedir.

Elicio Therapeutics, Inc. Temel Bilgiler Özeti

Elicio Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ELTX temel i̇stati̇sti̇kler
Piyasa değeri	US$182.12m
Kazançlar(TTM)	-US$40.18m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-4.6x

F/K Oranı

ELTX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ELTX gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$40.19m
Kazançlar	-US$40.18m

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.18
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	-659.4%

ELTX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/22 10:27
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Elicio Therapeutics, Inc. 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Robert Burns	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Boris Peaker	JonesTrading Institutional Services, LLC

Elicio Therapeutics (ELTX) Hisse Özeti

Risk Analizi

Top Community Narratives

Very Bullish

Top Community Narratives

Very Bullish

Elicio Therapeutics, Inc. Rakipler

Corbus Pharmaceuticals Holdings

Anika Therapeutics

Nkarta

Precision BioSciences

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Favorable Auction Dynamics

New major risk - Financial position

Valuation: 15x upside potential

Study on track for success

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

New minor risk - Shareholder dilution

Recent updates

Favorable Auction Dynamics

New major risk - Financial position

Valuation: 15x upside potential

Study on track for success

Elicio Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

New minor risk - Share price stability

10 mg adjuvant = 100% mKRAS specific T-cell response rate

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt In A Risky Way?

80-90% prob of success

Elicio Therapeutics, Inc. Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIF-7P Trial

Elicio Therapeutics, Inc. Appoints Marc J. Wolfgang, M.S. as Chief Technology Officer

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent

Elicio Therapeutics, Inc. Announces Additional Immunogenicity Data from the Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P

Elicio Therapeutics, Inc. to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

Elicio Therapeutics, Inc. Reports Robust T Cell Responses Across Diverse HLA Background in Ongoing Phase 2 AMPLIFY-7P Trial

Elicio Therapeutics, Inc. Announces Investigator-Initiated Phase 1 Trial to Be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

Is Elicio Therapeutics (NASDAQ:ELTX) Using Debt Sensibly?

Elicio Therapeutics, Inc. Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-Up Data in Nature Medicine for Minimal Residual Disease Positive, Adjuvant-Stage Patients

New major risk - Revenue and earnings growth

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

Elicio Therapeutics, Inc.(NasdaqCM:ELTX) dropped from Russell 3000E Growth Index

Elicio Therapeutics, Inc. announced that it expects to receive $10 million in funding

New major risk - Financial position

Elicio Therapeutics, Inc., Annual General Meeting, May 19, 2025

Elicio Therapeutics Appoints Preetam Shah as Chief Strategy and Financial Officer

Director exercised options to buy US$28m worth of stock.

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $10.000003 million.

New minor risk - Share price stability

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

New major risk - Financial position

Elicio Therapeutics, Inc. Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Elicio Therapeutics, Inc. Appoints Robert Connelly as Principal Accounting Officer and Principal Financial Officer

Price target decreased by 9.1% to US$10.00

Less than half of directors are independent

Elicio Therapeutics, Inc., Annual General Meeting, Nov 07, 2024

Elicio Therapeutics, Inc. announced that it expects to receive $20 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. has filed a Follow-on Equity Offering.

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-Driven Solid Tumors at the 2024 ASCO Annual Meeting

New major risk - Financial position

Elicio Therapeutics, Inc. announced that it has received $5.999999 million in funding from Gkcc, LLC

Elicio Therapeutics, Inc. Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

Elicio Therapeutics, Inc. Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study

Elicio Therapeutics, Inc. Publishes Updated Preliminary Phase 1 Data from AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002

Elicio Therapeutics, Inc. announced that it has received $7.04753 million in funding from Gkcc, Llc

Elicio Therapeutics, Inc. Announces Resignation of Annette Matthies as Chief Business Officer

Elicio Therapeutics, Inc. Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 At AACR Special Conference: Pancreatic Cancer

Less than half of directors are independent

Elicio Therapeutics, Inc. Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer

Elicio Therapeutics, Inc. completed the acquisition of Angion Biomedica Corp. (NasdaqGS:ANGN) from Vifor (International) AG, Eisa-Abc LLC and others in a reverse merger transaction.

Elicio Therapeutics, Inc. entered into a definitive merger agreement to acquire Angion Biomedica Corp. (NasdaqGS:ANGN) in a reverse merger transaction.

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Elicio Therapeutics, Inc. Temel Bilgiler Özeti

Kazanç ve Gelir

Şirket Analizi ve Finansal Veri Durumu